帕利伐米
帕利伐米 性质
| 熔点 | 106-107 ºC |
|---|---|
| 沸点 | 341.5±52.0 °C(Predicted) |
| 密度 | 1.411 |
| 储存条件 | Store at -20°C, protect from light, stored under nitrogen |
| 溶解度 | DMSO 中≥22.1 mg/mL；不溶于乙醇；温和加热和超声波下，水中≥19.4 mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 0.79±0.50(Predicted) |
| 颜色 | 白色至米白色 |
| InChI | InChI=1S/C4H11Cl2N2O2P/c5-1-3-7-11(9,10)8-4-2-6/h1-4H2,(H3,7,8,9,10) |
| InChIKey | BKCJZNIZRWYHBN-UHFFFAOYSA-N |
| SMILES | P(NCCCl)(NCCCl)(O)=O |
| CAS 数据库 | 31645-39-3 |
帕利伐米 用途与合成方法
Palifosfamide lysine (ZIO-201) is a stable form of palifosfamide. Palifosfamide lysine has broad activity in sarcoma lines in vitro . The IC 50 ranges from 2.25 ro 6.75 μM for most cell lines except OS222 (IC 50 =31.5 μM).
Tumor growth inhibition is seen in both OS31 and OS33 xenografts and the RMS xenograft resulting in a significant difference in event-free survival between the control and the treated groups. Differential gene expression of ALDH3A1 but not ALDH1A1 is noted in the OS31 xenograft. Stabilized palifosfamide administered to mice suppresses MX-1 tumor growth by greater than 80% with 17% complete antitumor responses. Oral bioavailability in rats is 48-73% of parenteral administration, and antitumor activity in mice is equivalent by both routes. Treatment with palifosfamide-tris combined with docetaxelor doxorubicin at optimal regimens results in complete tumor regression in 62-75% of mice.
帕利伐米 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-12-22 | HY-14798 | 帕利伐米 | 31645-39-3 | 1 mg | 680 |
| 2025-12-22 | HY-14798 | 帕利伐米 | 31645-39-3 | 5mg | 1700 |
